Assoc. Prof. Dr. Fadime Canbolat | Health Research | Best Researcher Award

Assoc. Prof. Dr. Fadime Canbolat | Canakkale Onsekiz Mart University | Turkey

Assoc. Prof. Dr. Fadime Canbolat is an accomplished Associate Professor of Pharmaceutical Toxicology with over a decade of academic, research, and laboratory expertise. She has made significant contributions to pharmacology, toxicology, therapeutic drug monitoring, precision medicine, and medical biotechnology. Throughout her career, she has successfully combined teaching, research, and laboratory management roles, demonstrating strong leadership in curriculum development, analytical method validation, bioanalytical studies, and risk assessment. With a proven track record of supervising graduate students, leading research projects, and publishing in reputed journals, Assoc. Prof. Dr. Fadime Canbolat has established herself as a dedicated scholar committed to advancing pharmaceutical sciences. Her multidisciplinary background integrates toxicological analysis, pharmacogenetics, and clinical pharmacology, enabling her to contribute meaningfully to both academic and applied research domains.

Professional Profile

ORCID

GOOGLE SCHOLAR

SCOPUS

Summary of Suitability

Assoc. Prof. Dr. Fadime Canbolat is a distinguished researcher, academician, and pharmaceutical toxicologist with professional and research experience in pharmacology, toxicology, precision medicine, and therapeutic drug monitoring. Her contributions span across academic teaching, advanced laboratory research, drug validation, nanoparticle-based drug delivery systems, molecular pharmacogenetics, and risk assessment studies, making her a highly qualified candidate for the Best Researcher Award.

Education

Assoc. Prof. Dr. Fadime Canbolat holds a Ph.D. in Pharmaceutical Toxicology from Yeditepe University, where her doctoral research focused on assessing the relationship between drug levels and cytochrome P450 enzyme activities in patients with genetic polymorphisms, integrating therapeutic drug monitoring and personalized medicine approaches. She also earned a Master’s degree in Pharmacology and Toxicology from Selçuk University, where she evaluated drug use patterns and prescription costs. Additionally, she pursued another Master’s degree in Visual Communication and Design at Uskudar University, enhancing her ability to integrate scientific visualization in medical research. Her undergraduate studies in Chemistry at Selçuk University provided a strong foundation in analytical sciences, which she later applied extensively in her toxicology research and teaching.

Experience

Assoc. Prof. Dr. Fadime Canbolat is currently serving as a Faculty Member at Canakkale Onsekiz Mart University, where she teaches and mentors students in pharmaceutical toxicology, pharmacology, and forensic sciences. Previously, she spent over eight years at Uskudar University’s Clinical Pharmacogenetics & Advanced Toxicology Laboratory, where she served as Laboratory Assistant Manager and later as Quality Manager. She successfully managed validation studies for therapeutic drug monitoring, developed analytical methods for various drug molecules, and contributed to the accreditation of the Advanced Toxicology Laboratory under ISO/IEC 17025 standards. Her teaching portfolio is equally extensive, having delivered courses in neuropharmacology, toxicology, pharmacogenetics, forensic chemistry, food-drug interactions, and instrumental analysis. She has also supervised numerous graduate students, guiding them in pharmacology, toxicology, and medical biotechnology research.

Research Interests

Assoc. Prof. Dr. Fadime Canbolat research interests span across several domains, including pharmaceutical toxicology, precision medicine, therapeutic drug monitoring (TDM), cytochrome P450 enzyme phenotyping, bioanalytical method development, and medical biotechnology. She is particularly focused on the clinical application of pharmacogenetics to optimize drug therapy based on individual genetic profiles. Her work also explores nanoparticle-based drug delivery systems, green synthesis of nanoparticles for biomedical applications, and risk assessment of elemental impurities in pharmaceuticals and dietary supplements. Furthermore, she is actively involved in evaluating antioxidant activity, genotoxicity, and molecular mechanisms underlying neurodegenerative and psychiatric disorders, making her research highly interdisciplinary and clinically relevant.

Awards

Assoc. Prof. Dr. Fadime Canbolat has received several recognitions for her academic and research contributions, including invitations to serve as a reviewer and editorial board member for international journals in pharmaceutical sciences. She has successfully led multiple competitive scientific research projects funded by national and institutional bodies, including studies on nanoparticle-based drug delivery systems, neuroprotective agents, precision medicine, and risk assessments in food and pharmaceuticals. Her innovative approach to integrating advanced analytical techniques with clinical pharmacology has positioned her as a leader in her field, making her a strong candidate for prestigious research awards.

Publication Top Notes

Chitosan Nanoparticles Loaded with Quercetin and Valproic Acid: A Novel Approach for Enhancing Antioxidant Activity against Oxidative Stress in the SH-SY5Y Human Neuroblastoma Cell Line

Comparison of Normal saline, Activated Charcoal and Intravenous Lipid Emulsion in a Rat Model of Colchicine Overdose: Experimental Study

Analysis of non-carcinogenic health risk assessment of elemental impurities in vitamin C supplements

Chitosan Nanoparticle Loaded with Quercetin and Valproic Acid: A Novel Approach for Enhancing Antioxidant Activity against Oxidative Stress in SH-SY5Y Cell Line

Evaluation of the Antidepressant Effect of Propolis in Chronic Unpredictable Mild Stress-induced Depression Model in Rats

Conclusion

Assoc. Prof. Dr. Fadime Canbolat is a highly dedicated academic and researcher whose contributions to pharmaceutical toxicology and pharmacogenetics are both innovative and impactful. Her extensive experience in research, teaching, laboratory management, and quality assurance demonstrates her leadership in advancing scientific knowledge and improving clinical practices. With an exceptional record of peer-reviewed publications, project leadership, and active involvement in multidisciplinary studies, she continues to make significant contributions to precision medicine, toxicological risk assessment, and nanoparticle-based drug delivery systems. Assoc. Prof. Dr. Fadime Canbolat commitment to scientific excellence, student mentorship, and collaborative research positions her as an outstanding candidate for award nomination, reflecting her influence on the advancement of pharmaceutical sciences globally.

Dr. Neeraj Thakur | AI in Healthcare | Best Researcher Award

Postdoctoral Fellow at University of Oklahoma Health Sciences, United States

Dr. Neeraj S. Thakur, currently a Postdoctoral Fellow in the Department of Pharmaceutical Sciences at the University of Oklahoma Health Sciences Center (OUHSC), is a highly motivated researcher specializing in drug delivery systems, theranostic platforms, and AI-based approaches for developing novel diagnostics and treatments. With over a decade of international research experience spanning the USA, Europe, and Asia, Dr. Thakur has led multiple projects related to nanomaterial design, formulation development, and the synthesis of advanced drug delivery systems for treating diseases like cancer and infections. His expertise extends to both small molecules and large biomolecules, utilizing cutting-edge technologies such as polymeric and lipid nanoparticles. He has an extensive publication record with 29 papers, five patents, six book chapters, and significant contributions to the field.

Profile

Scopus

Education

Dr. Thakur earned his Ph.D. in Pharmaceutical Technology (Biotechnology) from the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India, where his research focused on the development of nanoparticle-based fluorescent probes for biomedical applications. He also holds an M.Tech in Pharmaceutical Technology (Biotechnology) from NIPER, Mohali, where he was the class topper, and a B.Pharm degree from Shri G.S. Institute of Technology and Science, Indore. Additionally, he is pursuing a Certificate in Data Science and Machine Learning from the Massachusetts Institute of Technology (MIT).

Experience

Dr. Thakur has held significant roles in various research institutions. As a Postdoctoral Fellow at OUHSC, he established research laboratories and led projects on nanomaterial development for drug delivery systems targeting multiple applications, including inner ear and ocular delivery. Prior to this, he worked at the University of Geneva, Switzerland, where he developed hybrid micelle formulations for transdermal delivery and designed iontophoretic devices. He also contributed to the Center of Innovative and Applied Bioprocessing (CIAB), India, where he led the development of topical drug delivery systems and was involved in several patent filings. These experiences have honed his skills in formulation and analytical development, laboratory management, and industrial collaboration.

Research Interests

Dr. Thakur’s research interests focus on the development of advanced drug delivery systems, particularly using nanomaterials such as polymeric and lipid nanoparticles. His work aims to improve the therapeutic efficacy of drugs by enhancing their delivery to specific sites in the body, such as the inner ear, ocular tissues, and tumors. He is also dedicated to the integration of AI-based approaches for optimizing drug delivery design, ensuring more precise treatments for conditions like cancer and ototoxicity. His passion extends to the creation of theranostic platforms for early disease diagnosis and personalized medicine.

Awards

Throughout his career, Dr. Thakur has received numerous accolades for his contributions to pharmaceutical sciences. Notable among them are the John B. Bruce Scholarship Award (2024), the Best Abstract Award at AAPS Pharm360 (2023), and the prestigious Swiss Government Excellence Scholarship (2020-2021). His earlier achievements include the DST-INSPIRE and CSIR Research Fellowships, which are awarded to the top 1% of students in India. These recognitions underscore his impact on the scientific community and his leadership in advancing pharmaceutical research.

Publications

Dr. Thakur has authored 29 peer-reviewed papers, with some of his recent work focused on innovative drug delivery systems. Key publications include:

Thakur, N.S., et al., “Crosslinked Hybrid Nanoparticle Embedded in Thermogel For Sustained Co-Delivery to Inner Ear,” Journal of Nanobiotechnology, 2024.

Thakur, N.S., et al., “Progress and Promise of Photoresponsive Nanocarriers for Precision Drug Delivery in Cancer,” Journal of Photochemistry & Photobiology C: Photochemistry Reviews, 2024.

Thakur, N.S., et al., “Dual Stimuli-Responsive and Sustained Drug Delivery Nanosensogel for Prevention of Cisplatin-Induced Ototoxicity,” Journal of Controlled Release, 2024.

Paul, S., et al., “Co-Administration of Chemo-Phototherapeutic Loaded Lignin Nanoarchitecture for Skin Cancer and Bacterial Infections,” ACS Applied Nano Materials, 2024.

Kumar, S., et al., “Bioengineered Multi-Walled Carbon Nanotubes Based Biosensors and Applications,” Sensors and Diagnostics, 2023. These works, which cover nanomedicine, drug delivery, and nanomaterial innovation, have significantly contributed to the field of pharmaceutical sciences and have been widely cited.

Conclusion

Dr. Neeraj S. Thakur’s multifaceted career highlights his dedication to advancing pharmaceutical research through innovation in nanotechnology and drug delivery systems. His profound knowledge in both academic and industrial settings, along with his leadership in driving collaborative research projects, continues to position him as a key figure in his field. With a focus on precision medicine, AI-based design, and the development of targeted therapies, Dr. Thakur is making remarkable strides toward improving patient outcomes and advancing the future of drug delivery and diagnostics.